Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2021

View Archived Issues

Enrollment begins in phase I/II study of etrumadenant in metastatic colorectal cancer

Brain-penetrant ALK inhibitor NUV-655 active against treatment-resistant mutations

Phase I trials planned for new PARP1/2 inhibitor RP-12146

AP-101 appears to be safe and well tolerated in phase I study in ALS patients

Aurigene CD73 inhibitor AU-21218 inhibits tumor growth in vivo

First patients dosed in SAVE 1 phase IIa study ATI-2173

FDA clears IND application for APB-102 as treatment of SOD1 ALS

FDA grants IND approval for Zofin in the treatment of osteoarthritis

Dosing starts in phase I study of AL-102 in combination with WVT-078 in patients with MM

AUT-00206 improves auditory information processing in patients with schizophrenia

Novartis and Gilead Sciences patent compounds for herpes virus infections

Nirogyone Therapeutics discloses MCT inhibitors

Boragen identifies new JAK inhibitors

Innovo Therapeutics synthesizes new immunomodulators

Sangamo Therapeutics presents new compounds for prion diseases

UCB-0599 shows safety in older individuals with PD with age-related comorbidities

Targeting the adenosine pathway for cancer immunotherapy

SAB-185 studied as part of ACTIV-2 trial for treatment of COVID-19

AN-3025: an anti-TNFR2 antibody for cancer immunotherapy

Valneva begins pivotal trial of COVID-19 vaccine candidate VLA-2001

Treatment begins in clinical trial of GNT-0004 gene therapy for Duchenne muscular dystrophy

Bharat reports second interim analysis of phase III study of Covaxin COVID-19 vaccine candidate

PCSK9 affects antitumor immunity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...